<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01978405</url>
  </required_header>
  <id_info>
    <org_study_id>2013Wze088</org_study_id>
    <nct_id>NCT01978405</nct_id>
  </id_info>
  <brief_title>Short-Term Alpha Lipoic Acid Therapy for Prevention of Contrast-induced Acute Kidney Injury and Endothelial Dysfunction in Type 2 Diabetes</brief_title>
  <official_title>Short-Term Alpha Lipoic Acid Therapy for Prevention of Contrast-induced Acute Kidney Injury and Endothelial Dysfunction in Type 2 Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Xiang Guang-da</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Wuhan General Hospital of Guangzhou Military Command</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Contrast-induced acute kidney injury (CIAKI) is a major complication with adverse outcomes
      after contrast media injection. Although the risk of developing CIAKI is low in patients with
      normal renal function, it is dramatically higher in patients with conditions such as diabetes
      mellitus (DM) or chronic kidney disease (CKD). More recently, our data showed that contrast
      agents can induce endothelial dysfunction partially via free radicals in diabetes. Therefore,
      strategies to prevent CIAKI and endothelial dysfunction in DM patients with CKD are urgently
      needed. Alpha-lipoic acid and its reduced form, dihydrolipoate, are potent antioxidants. We
      hypothesized that alpha lipoic acid can prevent the contrast-induced acute kidney injury and
      endothelial dysfunction in type 2 diabetes.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>November 2013</start_date>
  <completion_date type="Anticipated">June 2014</completion_date>
  <primary_completion_date type="Anticipated">June 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Contrast induced acte kidney injury</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>The changes of endothelium-dependent arterial dilation before and after contrast administrated</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Acute Kidney Injury</condition>
  <condition>The Changes of Plasma Creatinine</condition>
  <condition>The Changes of Plasma Free Radicals</condition>
  <condition>The Changes of Endothelium-dependent Arterial Dilation</condition>
  <arm_group>
    <arm_group_label>alpha-lipoic acid group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Alpha lipoic acid 600 mg in 0.9% sodium chloride 250 ml was given before and after contrast agent was administrated.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo intervention group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Only 0.9% sodium chloride 250 ml was given for this group.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Alpha lipoic acid</intervention_name>
    <arm_group_label>alpha-lipoic acid group</arm_group_label>
    <arm_group_label>Placebo intervention group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  type 2 diabetes

          -  nephropathy (stage 3 and 4)

        Exclusion Criteria:

          -  recive alpha lipoic acid

          -  type 1 diabetes

          -  nephropathy (stagte 1, 2 and 5)

          -  hypersensitivity to contrast media

          -  IV heart failure

          -  lactic acidosis
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Xiang Guangda, MD</last_name>
    <role>Study Director</role>
    <affiliation>Wuhan General Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Xiang Guangda, MD</last_name>
    <phone>+8602768878410</phone>
    <email>Guangda64@hotmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Wuhan General Hospital</name>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <zip>430070</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xiang Guangda, MD</last_name>
      <phone>+8602768878410</phone>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>October 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 25, 2013</study_first_submitted>
  <study_first_submitted_qc>October 31, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 7, 2013</study_first_posted>
  <last_update_submitted>November 6, 2013</last_update_submitted>
  <last_update_submitted_qc>November 6, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 8, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Wuhan General Hospital of Guangzhou Military Command</investigator_affiliation>
    <investigator_full_name>Xiang Guang-da</investigator_full_name>
    <investigator_title>Director of Endocrinol Dept.</investigator_title>
  </responsible_party>
  <keyword>Type 2 diabetes</keyword>
  <keyword>Nephropathy</keyword>
  <keyword>Contrast medium</keyword>
  <keyword>Alpha lipoic acid</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Wounds and Injuries</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
    <mesh_term>Acute Kidney Injury</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thioctic Acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

